Skip to content
Open access

Niflumic Acid-Loaded Aspasomes as a Repurposed Nanoplatform: Antitumor Effects and Modulation of PI3K/AKT/mTOR Pathway-Related Molecular Markers in Solid Ehrlich Carcinoma-Bearing Mice

Nov 2026 · Pharmaceutics · 0 citations · 139 references

Abstract

Background/Objectives: Breast cancer remains a major global health challenge, with the PI3K/AKT/mTOR signaling axis playing a key role in tumor progression. Drug repurposing offers an efficient approach to cancer therapeutics. Niflumic acid (NIF), a selective cyclooxygenase-2 (COX-2) inhibitor, has demonstrated antiproliferative and pro-apoptotic effects against breast cancer cells; however, its therapeutic potential is limited by its poor solubility. This study aimed to develop, optimize, and evaluate NIF-loaded aspasomes (NIF-ASPs) against solid Ehrlich carcinoma (SEC). Methods: NIF-ASPs were optimized via a 21.41 full factorial design. The optimum (A2) formulation was evaluated for entrapment efficiency (EE%), vesicle size (VS), polydispersity index (PDI), zeta potential (ZP), and ex vivo permeation, using the skin as a model lipoidal barrier. Following intraperitoneal administration, the antitumor efficacy and associated changes in PI3K/AKT/mTOR signaling components were evaluated in SEC-bearing mice through RT-qPCR gene expression, biochemical assays, immunohistochemistry, and histopathology. Results: The optimal A2 formula exhibited an EE% of 94.83 ± 0.16%, VS of 205.55 ± 2.05 nm, PDI of 0.49 ± 0.00, ZP of −23.65 ± 0.35 mV, and about a 2.59-fold increase in skin permeation flux versus free NIF suspension. In vivo, A2 was associated with a tumor inhibition rate of 63% (NIF suspension, 51.56%). Molecular and biochemical investigations demonstrated that A2 treatment was accompanied by significant alterations in PI3K/AKT/mTOR-associated molecular markers, characterized by decreased PI3K and p-AKT levels, together with downregulation of AKT and mTOR expression. Additionally, A2 treatment resulted in significant reductions in BCL-2, p-BAD, COX-2, and MDA levels, accompanied by restoration of total antioxidant capacity and a marked increase in cleaved caspase-3 immunoreactivity. Conclusions: NIF-ASPs serve as an efficient delivery platform that significantly enhances the NIF ex vivo skin permeation and are associated with reduced tumor growth accompanied by alterations in the PI3K/AKT/mTOR pathway-related molecular markers, COX-2-related inflammation, and oxidative stress.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.